Toxic shock syndrome medical therapy

Jump to navigation Jump to search

Toxic shock syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Toxic Shock Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Toxic shock syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Toxic shock syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Toxic shock syndrome medical therapy

CDC on Toxic shock syndrome medical therapy

Toxic shock syndrome medical therapy in the news

Blogs on Toxic shock syndrome medical therapy

Directions to Hospitals Treating Toxic shock syndrome

Risk calculators and risk factors for Toxic shock syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The initial management of toxic shock syndrome involves the removal of any foreign materials such as tampons, vaginal sponges, or nasal packing. Antimicrobial therapy is indicated in toxic shock syndrome. Supportive therapy for toxic shock syndrome includes intravenous fluids, control of blood pressure, and dialysis in cases of renal failure. Patients with multiple organ failure are admitted to the intensive care unit.

Medical Therapy

Any foreign materials, such as tampons, vaginal sponges, or nasal packing, will be removed. Sites of infection (such as a surgical wound) will be drained. The goal of treatment is to maintain important body functions. This may include:

Sometimes it is required that patients are admitted to the intensive care unit for supportive care in case of multiple organ failure.

  • Staphylococcal toxic shock syndrome [1]
  • 1. Methicillin sensitive Staphylococcus aureus
  • Preferred regimen (1): Cloxacillin 250-500 mg PO qid (maximum dose: 4 g/24 hr)
  • Preferred regimen (2): Nafcillin 4-12 g/24 hr IV q4-6hr (maximum dose: 12 g/24 hr)
  • Preferred regimen (3): Cefazolin 0.5-2g IV/IM q8h (maximum dose: 12 g/24 hr), AND Clindamycin 150-600 mg IV/IM/PO q6-8h (maximum dose: 5 g/24 hr IV/IM or 2 g/24 hr PO)
  • Alternative regimen (1): Clarithromycin 250-500 mg PO q12h (maximum dose: 1 g/24 hr) AND Clindamycin 150-600 mg IV/IM/PO q6-8h (maximum dose: 5 g/24 hr IV/IM or 2 g/24 hr PO)
  • Alternative regimen (1): Rifampicin, AND Linezolid 600 mg IV/PO q12hr
  • Alternative regimen (2): Daptomycin
  • Alternative regimen (3): Tigecycline 100 mg IV loading dose followed by 50 mg q12h
  • 2. Methicillin resistant Staphylococcus aureus
  • Preferred regimen: Clindamycin 150-600 mg q6-8h IV/IM/PO (max dose: 5 g/24 hr IV or IM or 2 g/24 hr PO)
  • Preferred regimen: Linezolid 600 mg IV/PO q12h AND (Vancomycin 15 to 20 mg/kg IV q8-12h, not to exceed 2 g per dose or Teicoplanin)
  • Alternative regimen (1): Rifampicin AND Linezolid 600 mg IV/PO q12h
  • Alternative regimen (2): Daptomycin
  • Alternative regimen (3): Tigecycline 100 mg loading dose followed by 50 mg IV q12h
  • 3. Glycopeptide resistant or intermediate Staphylococcus aureus
  • Preferred regimen: Linezolid 600 mg IV/PO q12h AND Clindamycin 150-600 mg IM/IV/PO q6-8h (maximum dose: 5 g/24 hr IV/IM or 2 g/24 hr PO) (if sensitive)
  • Alternative regimen: Daptomycin OR Tigecycline 100 mg loading dose followed by 50 mg IV q12h
  • Streptococcal toxic shock syndrome [1]
  • 1. Group A streptococcus
  • Preferred regimen: Penicillin G, 2–4 MU IV q4–6h AND Clindamycin 600–900 mg q8h IV, (maximum dose: 5 g/24 hr IV/IM or 2 g/24 hr PO)
  • Alternative regimen (1): (Macrolide Azithromycin 500 mg PO day 1 followed by 250 mg for 4 days
  • Alternative regimen (2): Fluoroquinolone Oxacillin 2-12 g/24 hr divided q4-6h IV (maximum dose: 12 g/24 hr)), AND Clindamycin 150-600 mg q6-8h IV, IM, or PO (max dose: 5 g/24 hr IV/IM or 2 g/24 hr PO)
  • Alternative regimen (3): Linezolid 600 mg IV/PO q12h
  • Alternative regimen (4): Daptomycin OR Tigecycline 100 mg loading dose followed by 50 mg q12h IV
  • Note: Macrolide and Fluoroquinolone resistance increasing
  • 2. Macrolide, lincosamide, and streptogramin B (MLS) resistant group A streptococcus

References

  1. 1.0 1.1 Lappin E, Ferguson AJ (2009). "Gram-positive toxic shock syndromes". Lancet Infect Dis. 9 (5): 281–90. doi:10.1016/S1473-3099(09)70066-0. PMID 19393958.


Template:WikiDoc Sources